New Menopause Drug Cuts Hot Flashes by 65% in Trial

Women suffering through menopause may soon have their best treatment option yet, thanks to a new drug that dramatically reduces hot flashes without hormones.

AbCellera announced Monday that their Phase 2 trial of ABCL635 achieved remarkable results. Women taking the investigational antibody saw their daily hot flashes drop from 10 to just 3.5, a 65% reduction. Those on placebo only improved to 8.8 hot flashes per day.

The treatment targets a specific brain receptor called NK3R, which plays a key role in triggering hot flashes. Unlike hormone-based therapies, this approach sidesteps concerns many women have about traditional menopause treatments.

Even better, participants reported improved sleep quality with zero serious or severe side effects. That safety profile sets ABCL635 apart from current options like Veozah and Lynkuet, which have shown more concerning side effect patterns.

"If validated in Phase 3, ABCL635 could offer a new treatment option with a more convenient dosing regimen and potentially less toxicity," said Dr. JoAnn Pinkerton, Professor of Obstetrics and Gynecology at the University of Virginia School of Medicine.

The Ripple Effect

This breakthrough matters for more than just symptom relief. Menopause affects every woman who lives long enough, yet treatment options remain frustratingly limited. Many women avoid hormone therapy due to health concerns, leaving them to suffer through years of disrupted sleep, discomfort, and reduced quality of life.

A safer, more effective option could transform daily life for millions. Better sleep alone improves mood, productivity, relationships, and overall health. When women feel better, families and workplaces benefit too.

The antibody-based approach also opens doors for similar treatments targeting other menopause symptoms. If this mechanism proves successful, researchers may develop additional therapies using the same scientific principles.

AbCellera now moves toward Phase 3 trials, the final step before seeking FDA approval. If results hold up in larger studies, this could become the new gold standard for menopause care within a few years.

For women who've been told to simply endure hot flashes as a natural part of aging, science is finally catching up with compassion.